SGLT2 inhibition in the management of type 2 diabetes: Potential impact on CVD Risk

Prof Silvio E Inzucchi, Yale Diabetes Center, New Haven, CT, USA

Sep. 29, 2015

• T2DM pathogenesis 00:01
• SGLT2 Inhibitors: How do they work? 06:53
• Potential pathways to CV benefits of SGLT2-inhibitors based on clinical and mechanistic studies 11:01
• SGLT2 inhibitors and the kidney 16:20
• SGLT2 Inhibitors: Risks & Benefits  19:08
• 2015 ADA-EASD Position Statement on Management of Hyperglycemia in T2DM 22:40